During the 24 weeks of the study, the hepcidin levels were significantly reduced in patients treated with roxadustat, resulting in reduced degradation of ferroportin (FPN) [23] and increased iron absorption and release to avoid the occurrence of functional iron deficiency [24]. The gene discussed is HAMP; the disease is nutritional disorder.